@gingerw - That's actually a great question! Vismodegib, a Hedgehog pathway inhibitor, is approved for advanced basal cell carcinoma, not squamous cell carcinoma (SCC). Some case reports even suggest SCC may develop during or after vismodegib use for BCC, possibly due to transformation of the cells. Standard SCC treatments include immunotherapy (e.g., cemiplimab), chemotherapy, surgery, or radiation. Of course these would be great topics to discuss with your dermatologist.